Intrexon | XON - Interest Expense On Debt


Intrexon reported $2K in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Agenus USD 16.02M 2.85M Dec/2025
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Amgen USD 657M 4M Mar/2026
Anika Therapeutics 179.39M 556.84M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Incyte USD 569K 13K Mar/2026
Intrexon USD 2K 5K Jun/2024
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
MannKind USD 12.43M 1.44M Mar/2026
Merck USD 479M 67M Mar/2026
Novartis USD 343M 39M Mar/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 354M 11M Mar/2026
Veracyte USD 2K 1000 Dec/2023
Xencor USD 4.7M 2.65M Mar/2026